Key result
TAVR candidates with Généreux stage 3 and 4 cardiac damage warrant higher waitlist priority.
Why the study?
A substantial number of patients die while awaiting TAVR, and it is essential to stratify interventions to optimize patient triage on the waiting list.
Does Généreux's Aortic Stenosis staging predict waiting-list mortality in patients referred for TAVR?
Cohort
No
Does Généreux's Aortic Stenosis staging predict waiting-list mortality in patients referred for TAVR?
Patients at Généreux stages 3 and 4 have a more than twofold increased risk of death while on the TAVR waiting list and should be prioritized for intervention.
Answers are grounded in this paper and cite their sources.
May warrant higher TAVR priority for Généreux stages 3-4; extends cardiac damage staging to waitlist triage.
AIMS: Access to transcatheter aortic valve replacement (TAVR) is generally prioritized for symptomatic patients presenting with severe heart failure, syncope, angina, and decrease in left ventricular ejection fraction <40%. However, a substantial number of patients die while awaiting TAVR. In response to rising demand driven by an ageing population, it is essential to stratify interventions, as proposed by Généreux's Aortic Stenosis staging. METHODS AND RESULTS: We conducted a retrospective, single-center, longitudinal study in patients referred for TAVR. We specifically analysed the characteristics of 98 patients who died while on the TAVR waiting list. The primary outcome was all-cause mortality from the time of a patient's inclusion on the TAVR waiting list or non-proceeding to TAVR. The overall proportion of deceased patients was 8.4% [95% confidence interval (CI), 6.9-10.1] and 4% when excluding deaths occurring after 2019. By 3 months, 61.2% of patients had undergone TAVR, and this increased to 85.4% at 6 months. Deaths occurred in 6.3% of patients by 3 months and 7.8% by 6 months. We notice that 90% of deaths took place within the first 3 months. Multivariable analysis identified several variables independently associated with mortality on the TAVR waiting list: prior myocardial infarction [subdistribution hazard ratio (sHR), 1.87 (95% CI, 1.12-3.13); P = 0.017] and pulmonary artery systolic pressure > 60 mmHg [sHR, 2.37 (95% CI, 1.36-4.12); P = 0.002]. Généreux stages 3 and 4 showed a strong association with waiting-list mortality, more than doubling the risk of death [sHR, 2.12 (95% CI, 1.33-3.38); P = 0.002]. CONCLUSION: These findings suggest that TAVR candidates at Généreux stages 3 and 4 should receive higher priority on the waiting list.
No takes yet. Share an insight, caveat, or question.
Boyer et al. (2026) conducted a cohort in Aortic Stenosis (referred for TAVR). Généreux stages 3 and 4 vs. Lower Généreux stages was evaluated on All-cause mortality from the time of inclusion on the TAVR waiting list or non-proceeding to TAVR (sHR 2.12, 95% CI 1.33-3.38, p=0.002). Généreux stages 3 and 4 were strongly associated with waiting-list mortality among TAVR candidates, more than doubling the risk of death.
Synapse has enriched 10 related papers. Consider them for comparative context: